NIHR Newcastle Biomedical Research Centre

Background: in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives: to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations: sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions: EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification.

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and non-stigmatising, and can improve awareness and patient identification.

Dendritic cells (DC) are a class of bone-marrow-derived cells arising from lympho-myeloid haematopoiesis that form an essential interface between the innate sensing of pathogens and the activation of adaptive immunity. This task requires a wide range of mechanisms and responses, which are divided between three major DC subsets: plasmacytoid DC (pDC), myeloid/conventional DC1 (cDC1) and myeloid/conventional DC2 (cDC2). Each DC subset develops under the control of a specific repertoire of transcription factors involving differential levels of IRF8 and IRF4 in collaboration with PU.1, ID2, E2-2, ZEB2, KLF4, IKZF1 and BATF3. DC haematopoiesis is conserved between mammalian species and is distinct from monocyte development. Although monocytes can differentiate into DC, especially during inflammation, most quiescent tissues contain significant resident populations of DC lineage cells. An extended range of surface markers facilitates the identification of specific DC subsets although it remains difficult to dissociate cDC2 from monocyte-derived DC in some settings. Recent studies based on an increasing level of resolution of phenotype and gene expression have identified pre-DC in human blood and heterogeneity among cDC2. These advances facilitate the integration of mouse and human immunology, support efforts to unravel human DC function in vivo and continue to present new translational opportunities to medicine.

Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need 6,7 . Here we report the progressive accumulation of exhausted, unconventionally activated CD8 + PD1 + T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8 + PD1 + T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH–HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8 + PD1 + CXCR6 + , TOX + , and TNF + T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8 + T cells or TNF neutralization, suggesting that CD8 + T cells help to induce NASH–HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8 + PD1 + T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH–HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.

Abstract Analysis of human blood immune cells provides insights into the coordinated response to viral infections such as severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19). We performed single-cell transcriptome, surface proteome and T and B lymphocyte antigen receptor analyses of over 780,000 peripheral blood mononuclear cells from a cross-sectional cohort of 130 patients with varying severities of COVID-19. We identified expansion of nonclassical monocytes expressing complement transcripts ( CD16 + C1QA/B/C + ) that sequester platelets and were predicted to replenish the alveolar macrophage pool in COVID-19. Early, uncommitted CD34 + hematopoietic stem/progenitor cells were primed toward megakaryopoiesis, accompanied by expanded megakaryocyte-committed progenitors and increased platelet activation. Clonally expanded CD8 + T cells and an increased ratio of CD8 + effector T cells to effector memory T cells characterized severe disease, while circulating follicular helper T cells accompanied mild disease. We observed a relative loss of IgA2 in symptomatic disease despite an overall expansion of plasmablasts and plasma cells. Our study highlights the coordinated immune response that contributes to COVID-19 pathogenesis and reveals discrete cellular components that can be targeted for therapy.

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification.

BACKGROUND: This review, which focused on faculty development initiatives designed to improve teaching effectiveness, synthesized findings related to intervention types, study characteristics, individual and organizational outcomes, key features, and community building. METHODS: This review included 111 studies (between 2002 and 2012) that met the review criteria. FINDINGS: Overall satisfaction with faculty development programs was high. Participants reported increased confidence, enthusiasm, and awareness of effective educational practices. Gains in knowledge and skills, and self-reported changes in teaching behaviors, were frequently noted. Observed behavior changes included enhanced teaching practices, new educational initiatives, new leadership positions, and increased academic output. Organizational changes were infrequently explored. Key features included evidence-informed educational design, relevant content, experiential learning, feedback and reflection, educational projects, intentional community building, longitudinal program design, and institutional support. CONCLUSION: This review holds implications for practice and research. Moving forward, we should build on current success, broaden the focus beyond individual teaching effectiveness, develop programs that extend over time, promote workplace learning, foster community development, and secure institutional support. We should also embed studies in a theoretical framework, conduct more qualitative and mixed methods studies, assess behavioral and organizational change, evaluate transfer to practice, analyse key features, and explore the role of faculty development within the larger organizational context.

BACKGROUND: The burden of non-alcoholic fatty liver disease (NAFLD) is increasing globally, and a major priority is to identify patients with non-alcoholic steatohepatitis (NASH) who are at greater risk of progression to cirrhosis, and who will be candidates for clinical trials and emerging new pharmacotherapies. We aimed to develop a score to identify patients with NASH, elevated NAFLD activity score (NAS≥4), and advanced fibrosis (stage 2 or higher [F≥2]). METHODS: This prospective study included a derivation cohort before validation in multiple international cohorts. The derivation cohort was a cross-sectional, multicentre study of patients aged 18 years or older, scheduled to have a liver biopsy for suspicion of NAFLD at seven tertiary care liver centres in England. This was a prespecified secondary outcome of a study for which the primary endpoints have already been reported. Liver stiffness measurement (LSM) by vibration-controlled transient elastography and controlled attenuation parameter (CAP) measured by FibroScan device were combined with aspartate aminotransferase (AST), alanine aminotransferase (ALT), or AST:ALT ratio. To identify those patients with NASH, an elevated NAS, and significant fibrosis, the best fitting multivariable logistic regression model was identified and internally validated using boot-strapping. Score calibration and discrimination performance were determined in both the derivation dataset in England, and seven independent international (France, USA, China, Malaysia, Turkey) histologically confirmed cohorts of patients with NAFLD (external validation cohorts). This study is registered with ClinicalTrials.gov, number NCT01985009. FINDINGS: Between March 20, 2014, and Jan 17, 2017, 350 patients with suspected NAFLD attending liver clinics in England were prospectively enrolled in the derivation cohort. The most predictive model combined LSM, CAP, and AST, and was designated FAST (FibroScan-AST). Performance was satisfactory in the derivation dataset (C-statistic 0·80, 95% CI 0·76-0·85) and was well calibrated. In external validation cohorts, calibration of the score was satisfactory and discrimination was good across the full range of validation cohorts (C-statistic range 0·74-0·95, 0·85; 95% CI 0·83-0·87 in the pooled external validation patients' cohort; n=1026). Cutoff was 0·35 for sensitivity of 0·90 or greater and 0·67 for specificity of 0·90 or greater in the derivation cohort, leading to a positive predictive value (PPV) of 0·83 (84/101) and a negative predictive value (NPV) of 0·85 (93/110). In the external validation cohorts, PPV ranged from 0·33 to 0·81 and NPV from 0·73 to 1·0. INTERPRETATION: The FAST score provides an efficient way to non-invasively identify patients at risk of progressive NASH for clinical trials or treatments when they become available, and thereby reduce unnecessary liver biopsy in patients unlikely to have significant disease. FUNDING: Echosens and UK National Institute for Health Research.

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics - from epidemiology, awareness, care and treatment to public health policies and leadership - that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD.

Thymus development, cell by cell The human thymus is the organ responsible for the maturation of many types of T cells, which are immune cells that protect us from infection. However, it is not well known how these cells develop with a full immune complement that contains the necessary variation to protect us from a variety of pathogens. By performing single-cell RNA sequencing on more than 250,000 cells, Park et al. examined the changes that occur in the thymus over the course of a human life. They found that development occurs in a coordinated manner among immune cells and with their developmental microenvironment. These data allowed for the creation of models of how T cells with different specific immune functions develop in humans. Science , this issue p. eaay3224

The cellular landscape of the human intestinal tract is dynamic throughout life, developing in utero and changing in response to functional requirements and environmental exposures. Here, to comprehensively map cell lineages, we use single-cell RNA sequencing and antigen receptor analysis of almost half a million cells from up to 5 anatomical regions in the developing and up to 11 distinct anatomical regions in the healthy paediatric and adult human gut. This reveals the existence of transcriptionally distinct BEST4 epithelial cells throughout the human intestinal tract. Furthermore, we implicate IgG sensing as a function of intestinal tuft cells. We describe neural cell populations in the developing enteric nervous system, and predict cell-type-specific expression of genes associated with Hirschsprung's disease. Finally, using a systems approach, we identify key cell players that drive the formation of secondary lymphoid tissue in early human development. We show that these programs are adopted in inflammatory bowel disease to recruit and retain immune cells at the site of inflammation. This catalogue of intestinal cells will provide new insights into cellular programs in development, homeostasis and disease.

TEST 02 - Elsevier's Scopus, the largest abstract and citation database of peer-reviewed literature. Search and access research from the science, technology, medicine, social sciences and arts and humanities fields.

BACKGROUND: Lifestyle interventions focusing on weight loss remain the cornerstone of non-alcoholic fatty liver disease (NAFLD) management. Despite this, the weight losses achieved in research trials are not easily replicated in the clinic and there is an urgent need for therapies independent of weight loss. Aerobic exercise is not well sustained and the effectiveness of the better tolerated resistance exercise upon liver lipid and mediators of liver lipid has not been assessed. METHODS: Sedentary adults with clinically defined NAFLD were assigned to 8 weeks of resistance exercise (n=11) or continued normal treatment (n=8). RESULTS: 8 weeks of resistance exercise elicited a 13% relative reduction in liver lipid (14.0 ± 9.1 vs. 12.2 ± 9.0; p<0.05). Lipid oxidation (submaximal RQ -0.020 ± 0.010 vs. -0.004 ± 0.003; p<0.05), glucose control (-12% vs. +12% change AUC; p<0.01) and homeostasis model assessment insulin resistance (5.9 ± 5.9 to 4.6 ± 4.6 vs. 4.7 ± 2.1 to 5.1 ± 2.5; p<0.05) were all improved. Resistance exercise had no effect on body weight, visceral adipose tissue volume, or whole body fat mass (p>0.05). CONCLUSION: This is the first study to demonstrate that resistance exercise specifically improves NAFLD independent of any change in body weight. These data demonstrate that resistance exercise may provide benefit for the management for non-alcoholic fatty liver, and the long-term impact of this now requires evaluation.

The skin confers biophysical and immunological protection through a complex cellular network established early in embryonic development. We profiled the transcriptomes of more than 500,000 single cells from developing human fetal skin, healthy adult skin, and adult skin with atopic dermatitis and psoriasis. We leveraged these datasets to compare cell states across development, homeostasis, and disease. Our analysis revealed an enrichment of innate immune cells in skin during the first trimester and clonal expansion of disease-associated lymphocytes in atopic dermatitis and psoriasis. We uncovered and validated in situ a reemergence of prenatal vascular endothelial cell and macrophage cellular programs in atopic dermatitis and psoriasis lesional skin. These data illustrate the dynamism of cutaneous immunity and provide opportunities for targeting pathological developmental programs in inflammatory skin diseases.

Sarcopenia is a skeletal muscle disorder that commonly occurs with advancing age as well as with a number of long-term conditions. Recognition in clinical practice is relatively recent but important because of the association between sarcopenia and a range of adverse effects on health including impaired mobility, increased morbidity and mortality. Originally characterised as loss of muscle mass, the definition has evolved to focus on loss of skeletal muscle function, particularly strength, through a number of international definitions such as that of the European Working Group on Sarcopenia in Older People most recently revised in 2019. Progress in the decades ahead is likely to be seen with regard to use of routine health data, prescription of resistance exercise, translation of biology and epidemiology into first in man studies for new treatments, and focus on sarcopenia in low and middle-income countries. Immediate next steps include the newly formed Global Leadership Initiative on Sarcopenia to develop international consensus on definition and diagnosis.

Chronic liver disease (CLD) and its associated complications (cirrhosis and liver cancer) cause significant mortality, morbidity, and economic burden. Published data from the World Health Organization and/or the Global Burden of Disease show that the burden of CLD is large and increasing, primarily owing to the increasing burden of nonalcoholic fatty liver disease and alcohol-related liver disease (ALD). Middle Eastern, Northern African, and Asian regions of the globe are most affected by hepatitis B and hepatitis C virus. Furthermore, Middle Eastern and North African regions also are affected by nonalcoholic fatty liver disease, and Eastern European, West African, and Central Asian regions are affected by ALD. In this context, the rate of increase for cirrhosis is highest in the Middle East, as well as in middle high and high sociodemographic index (SDI) regions. On the other hand, the highest SDI countries are experiencing increasing rates of hepatocellular carcinoma (HCC). Assessing HCC burden based on country and etiology shows that China, Korea, India, Japan, and Thailand have the highest hepatitis B virus–related HCC cases, while China, Japan, and the United States have the highest hepatitis C virus–related HCC cases. Additionally, the United States has the highest ALD-related HCC cases, while India, the United States, and Thailand have the highest nonalcoholic steatohepatitis–related HCC cases. Although the burden of CLD is increasing globally, regions of the world are impacted differently as a result of a number of sociodemographic factors. Chronic liver disease (CLD) and its associated complications (cirrhosis and liver cancer) cause significant mortality, morbidity, and economic burden. Published data from the World Health Organization and/or the Global Burden of Disease show that the burden of CLD is large and increasing, primarily owing to the increasing burden of nonalcoholic fatty liver disease and alcohol-related liver disease (ALD). Middle Eastern, Northern African, and Asian regions of the globe are most affected by hepatitis B and hepatitis C virus. Furthermore, Middle Eastern and North African regions also are affected by nonalcoholic fatty liver disease, and Eastern European, West African, and Central Asian regions are affected by ALD. In this context, the rate of increase for cirrhosis is highest in the Middle East, as well as in middle high and high sociodemographic index (SDI) regions. On the other hand, the highest SDI countries are experiencing increasing rates of hepatocellular carcinoma (HCC). Assessing HCC burden based on country and etiology shows that China, Korea, India, Japan, and Thailand have the highest hepatitis B virus–related HCC cases, while China, Japan, and the United States have the highest hepatitis C virus–related HCC cases. Additionally, the United States has the highest ALD-related HCC cases, while India, the United States, and Thailand have the highest nonalcoholic steatohepatitis–related HCC cases. Although the burden of CLD is increasing globally, regions of the world are impacted differently as a result of a number of sociodemographic factors. Chronic liver disease (CLD) and associated cirrhosis accounts for approximately 1 million deaths per year. In addition to its clinical burden, CLD causes significant morbidity, impairment of health-related quality of life (HRQL), and economic burden.1Asrani S.K. Devarbhavi H. Eaton J. Kamath P.S. Burden of liver diseases in the world.J Hepatol. 2019; 70: 151-171Abstract Full Text Full Text PDF PubMed Scopus (1522) Google Scholar Although there are a number of causes of liver disease, the 4 major drivers of this CLD-related burden include chronic hepatitis C virus (CHC), chronic hepatitis B virus (CHB), alcohol-related liver disease (ALD), and nonalcoholic fatty liver disease (NAFLD). In fact, given the pandemic of obesity, its associated liver disease, NAFLD, is increasing and is predicted to continue to do so.2Paik J.M. Golabi P. Younossi Y. et al.Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD.Hepatology. 2020; 72: 1605-1616Crossref PubMed Scopus (272) Google Scholar, 3Estes C. Anstee Q.M. Arias-Loste M.T. et al.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.J Hepatol. 2018; 69: 896-904Abstract Full Text Full Text PDF PubMed Scopus (876) Google Scholar, 4Estes C. Razavi H. Loomba R. et al.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology. 2018; 67: 123-133Crossref PubMed Scopus (1108) Google Scholar, 5Estes C. Chan H.L.Y. Chien R.N. et al.Modelling NAFLD disease burden in four Asian regions-2019-2030.Aliment Pharmacol Ther. 2020; 51: 801-811Crossref PubMed Scopus (66) Google Scholar, 6World Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Scholar, 7World Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar, 8Rehm J. Gmel Sr., G.E. Gmel G. et al.The relationship between different dimensions of alcohol use and the burden of disease-an update.Addiction. 2017; 112: 968-1001Crossref PubMed Scopus (593) Google Scholar, 9Rehm J. Imtiaz S. A narrative review of alcohol consumption as a risk factor for global burden of disease.Subst Abuse Treat Prev Policy. 2016; 11: 37Crossref PubMed Scopus (105) Google Scholar, 10Messina J.P. Humphreys I. Flaxman A. et al.Global distribution and prevalence of hepatitis C virus genotypes.Hepatology. 2015; 61: 77-87Crossref PubMed Scopus (1173) Google Scholar, 11Schwarzinger M. Baillot S. Y. et use and the burden of chronic hepatitis C in France, a Hepatol. 2017; 67: Full Text Full Text PDF PubMed Scopus Google Scholar, J. Global burden of alcohol use and alcohol liver 2019; PubMed Scopus Google Scholar, Golabi P. J.M. et al.The global of nonalcoholic fatty liver disease and a review and PubMed Scopus Google Scholar the of CLD is for and global to this review an of the burden and to 4 major causes of CLD from a global the World Health Organization that million have approximately million and approximately deaths Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar Furthermore, is that million and are highest burden of is in the Eastern and by the and the Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Disease by Global Organization liver B million million most Eastern million most and million most C million million million most Eastern regions of the million million million per million from most and million million most Eastern and fatty liver by the as a million are to have NAFLD per most Middle and North by China, India, and highest rate per burden of mortality and life liver deaths for of liver highest life Eastern West Central of of and prevalence of deaths from liver of liver of is alcohol-related liver Global Burden of World Health from et M. M. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar Global on hepatitis World Health Scholar in hepatitis C virus prevalence and of between and a Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar and and of hepatitis B virus in a Hepatol. 2018; Full Text Full Text PDF PubMed Scopus Google Scholar in a alcohol-related liver Global Burden of World Health from et M. M. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar Global on hepatitis World Health Scholar in hepatitis C virus prevalence and of between and a Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar and and of hepatitis B virus in a Hepatol. 2018; Full Text Full Text PDF PubMed Scopus Google Scholar In addition to the the disease burden data for CLD from the global burden of disease for Health and an global the of is for the and for Health and accessed: December 13, 2022Google Scholar of and is to data to and that the global in for Health and accessed: December 13, 2022Google Scholar of the that use to for of accessed: December 13, 2022Google Scholar that are to the global burden of for Health and accessed: December 13, 2022Google accessed: December 13, 2022Google Scholar global impact of data has in a by the global M. M. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar that the prevalence of hepatitis C virus in million cases, for million and for million cases. a million deaths to for of the rate for per M. M. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar the of for Y. et of and for hepatitis B virus and hepatitis C virus an by and 2020; Full Text Full Text PDF PubMed Scopus Google Scholar, Y. et for hepatitis in and 2019; Full Text Full Text PDF PubMed Scopus Google Scholar, M.T. S. M. et al.Global of for chronic hepatitis C virus a review and PubMed Scopus Google Scholar, A. et for the of chronic hepatitis C virus a review and 2020; Full Text Full Text PDF PubMed Scopus Google Scholar, R. et for the of hepatitis C virus a review of Hepatol. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar the cause of the cause for of life the cause for of life and the cause for A large of to are for by the of Y. et of and for hepatitis B virus and hepatitis C virus an by and 2020; Full Text Full Text PDF PubMed Scopus Google Scholar In other of Asian and African regions the highest prevalence of for the countries of the Central African and the burden of for to countries the highest burden for and to are given the that data that of have and of S. C. et al.Global of of hepatitis B and hepatitis Hepatol. Full Text Full Text PDF PubMed Google S. et hepatitis B and C in the and from and global PubMed Scopus Google Scholar In countries are on to hepatitis by and the countries the highest burden of the Global on hepatitis World Health S. et of global and data Scholar In addition to and the global to an on the of in hepatitis C virus prevalence and of between and a Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar have that there million the of to Eastern and Central have the highest prevalence of while the number of of is in and is that an of million the of of hepatocellular and are to increase by to increase from that of have and have significant in the in hepatitis C virus prevalence and of between and a Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar that million in million and an deaths owing to cirrhosis and hepatocellular Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar burden of is highest in the by as well as the Eastern and the Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar the global prevalence to million of hepatitis B virus B and burden of hepatitis a for the Global Burden of Disease Hepatol. Full Text Full Text PDF PubMed Google Scholar also that in there B and burden of hepatitis a for the Global Burden of Disease Hepatol. Full Text Full Text PDF PubMed Google J.M. Younossi Y. et in the global burden of hepatitis B Full Text Full Text PDF PubMed Scopus Google Scholar that there has a in the prevalence of between and most J.M. Younossi Y. et in the global burden of hepatitis B Full Text Full Text PDF PubMed Scopus Google Scholar this in rates are to increase in owing to the of the as well as that is to the prevalence rates a in global hepatitis B is of the world PubMed Google Scholar, et of hepatitis B in countries Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar, et B impact and the for in PubMed Scopus Google Scholar to the burden of for the countries and B also have a on and of hepatitis B virus in a Hepatol. 2018; Full Text Full Text PDF PubMed Scopus Google Scholar that the global prevalence of hepatitis B in to approximately million cases. of have and of have In of are in and from and the global hepatitis B is of the world PubMed Google Scholar, et of hepatitis B in countries Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar, et B impact and the for in PubMed Scopus Google Scholar to rates of and in regions. in of of the hepatitis B of et B impact and the for in PubMed Scopus Google Scholar data for that to on the regions the highest burden of to and this cause of global hepatitis B is of the world PubMed Google Scholar, et of hepatitis B in countries Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar, et B impact and the for in PubMed Scopus Google Scholar On a is that countries the to hepatitis B prevalence in to by On the other hand, the highest prevalence are to the S. C. et al.Global of of hepatitis B and hepatitis Hepatol. Full Text Full Text PDF PubMed Google Scholar In addition to is a major cause of CLD Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar the of on the of alcohol is J. Gmel Sr., G.E. Gmel G. et al.The relationship between different dimensions of alcohol use and the burden of disease-an update.Addiction. 2017; 112: 968-1001Crossref PubMed Scopus (593) Google Scholar In given that alcohol consumption is associated for burden are to J. Gmel Sr., G.E. Gmel G. et al.The relationship between different dimensions of alcohol use and the burden of disease-an update.Addiction. 2017; 112: 968-1001Crossref PubMed Scopus (593) Google J. Imtiaz S. A narrative review of alcohol consumption as a risk factor for global burden of disease.Subst Abuse Treat Prev Policy. 2016; 11: 37Crossref PubMed Scopus (105) Google Scholar Furthermore, other liver in is to the for liver J.P. Humphreys I. Flaxman A. et al.Global distribution and prevalence of hepatitis C virus genotypes.Hepatology. 2015; 61: 77-87Crossref PubMed Scopus (1173) Google M. Baillot S. Y. et use and the burden of chronic hepatitis C in France, a Hepatol. 2017; 67: Full Text Full Text PDF PubMed Scopus Google Scholar data from the Global on and Health have the burden of J. Global burden of alcohol use and alcohol liver 2019; PubMed Scopus Google Scholar that alcohol consumption of the deaths to CLD in and of liver disease to deaths Furthermore, of of CLD to ALD. is that the highest rates to in Eastern European, West African, and Central Asian J. Global burden of alcohol use and alcohol liver 2019; PubMed Scopus Google Scholar Although the for alcohol use and associated prevalence of ALD. is owing to a of and that the to and have that alcohol is for of deaths from liver disease and of liver deaths use and burden for countries and a for the Global Burden of Disease 2018; Full Text Full Text PDF PubMed Scopus Google Scholar has impacted the burden of to impact most regions of the In and the countries affected NAFLD is as the most cause of CLD in different regions of the J.M. Golabi P. Younossi Y. et al.Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD.Hepatology. 2020; 72: 1605-1616Crossref PubMed Scopus (272) Google Scholar NAFLD is by the as an Health of disease for accessed: Scholar, burden of risk in countries and a for the Global Burden of Disease 2020; Full Text Full Text PDF PubMed Scopus Google Scholar, H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar the global prevalence for NAFLD have and most that the global prevalence for NAFLD is the data from to the NAFLD prevalence to as high as Golabi P. J.M. et al.The global of nonalcoholic fatty liver disease and a review and PubMed Scopus Google Scholar for the burden of NAFLD are the for liver complications (cirrhosis and liver cancer) to NAFLD and data for the prevalence of accessed: December 13, 2022Google Scholar the use of the data have that the NAFLD prevalence for has from in to in an of burden of risk in countries and a for the Global Burden of Disease 2020; Full Text Full Text PDF PubMed Scopus Google Scholar the global prevalence of NAFLD increasing by approximately J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar In in for of the global and of the global NAFLD liver rates by China, India, and highest NAFLD prevalence rate in the Middle and North In addition to the increasing NAFLD liver rates also have by the highest NAFLD liver deaths in Central deaths per J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar In a NAFLD to have the highest prevalence the liver diseases and the Middle the most affected of the countries the burden of NAFLD United and accessed: December 13, 2022Google Scholar NAFLD data the global of disease burden from North and to Middle Eastern and North African, and North has a high NAFLD prevalence rate of an of from to In rates to NAFLD also in North an of from to an of to J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar Eastern the highest NAFLD prevalence rate in a rate increase of for and for Central the highest NAFLD prevalence rate in a a NAFLD prevalence rate of in in to Eastern and Central rate of increase to and In addition to the high prevalence of NAFLD, Eastern also the highest liver rate from NAFLD for to the highest liver rate from NAFLD in a rate of in liver rate to from to to the from to that the liver rate from NAFLD increasing Central the liver rate from NAFLD in to and to J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar that from to the global deaths from liver to NAFLD liver deaths to other liver diseases and J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar also has a for disease risk that to in is in risk and in are to for 1 risk include alcohol and to and and high high and burden of risk in countries and a for the Global Burden of Disease 2020; Full Text Full Text PDF PubMed Scopus Google Scholar In the review of risk the in risk to high and high index of are associated are to NAFLD and nonalcoholic in the burden of risk to that for and to and burden of risk in countries and a for the Global Burden of Disease 2020; Full Text Full Text PDF PubMed Scopus Google H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar In fact, the global deaths and to high are to have for and H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar Although the rate of deaths has by for and by for H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar the of NAFLD, major drivers of in the In the rate of cirrhosis per for a increase and the rate by regions of the an rate of per in per in and per in of chronic liver disease and Hepatol. 2020; Full Text Full Text PDF PubMed Scopus Google Scholar review data that the number of of cirrhosis from to by in the rate per cirrhosis prevalence by the global and the highest number of cases. growing regions the and while the of the United the Furthermore, the highest for and the United the increase by in and the On the other hand, the in cirrhosis M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google of by Chronic Disease B C fatty liver disease and liver increase from to number of and regions are regions are for Eastern and North regions and United United United and increasing and increasing increasing United increasing and increasing in middle high and high in the middle SDI in SDI regions increasing in Eastern and North in SDI the middle and middle high in SDI nonalcoholic from et M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar the accessed: Scholar and the Global Burden of Disease and burden of cirrhosis by cause in countries and a for the Global Burden of Disease Hepatol. 2020; Full Text Full Text PDF PubMed Scopus Google Scholar in a nonalcoholic from et M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar the accessed: Scholar and the Global Burden of Disease and burden of cirrhosis by cause in countries and a for the Global Burden of Disease Hepatol. 2020; Full Text Full Text PDF PubMed Scopus Google Scholar is to that in the etiology of cirrhosis while of and cirrhosis M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar of cirrhosis for and an of and to etiology of liver disease, a for and M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar also prevalence by SDI is a countries other on the of of per and SDI is on a of to 1 an the highest of the United and an the of of the the world 1 of SDI high and SDI has to accessed: Scholar from to the most in cirrhosis in the and high SDI M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar in causes of cirrhosis are prevalence of cirrhosis for by the number of cases, the increase of cirrhosis while the highest in the for cirrhosis to in SDI in the middle SDI regions as well as global M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar cirrhosis prevalence by the number of cases, the United the increase in highest in the increase in In the most in in the in SDI regions increasing for Eastern and North are M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar to ALD-related cirrhosis prevalence by of cirrhosis by alcohol in and SDI regions. Although the highest number of cases, and the highest In the in SDI regions and in regions for and the rate of ALD-related cirrhosis to M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar liver cirrhosis has to the etiology of for of use and burden for countries and a for the Global Burden of Disease 2018; Full Text Full Text PDF PubMed Scopus Google Scholar In fact, the increase to a increase in the number of to In this context, the number of in the United the highest in SDI regions in the middle and middle high M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar in cirrhosis for of global deaths million Although the number of of deaths the rate from per to per the highest deaths per while the deaths per Eastern and Central increasing deaths owing to alcohol-related liver the country the in and highest in the in deaths by liver disease from to and burden of cirrhosis by cause in countries and a for the Global Burden of Disease Hepatol. 2020; Full Text Full Text PDF PubMed Scopus Google Scholar In addition to hepatocellular carcinoma is of CLD G. J. M. on hepatitis B by the global burden of liver disease to hepatitis B and PubMed Scopus Google Scholar and Burden of Disease J.M. et mortality, of life and life for from to a for the Global Burden of Disease PubMed Scopus Google Scholar, Chan et on Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar In this context, most of the of liver are to the rate of HCC to an of is the rate of per in a of to Although the rates are continue to have a rate for H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar rate is most owing to the rates of HCC for and and rates for NAFLD and ALD. rate are most a result of the of different global as for of M. M. et in and burden and quality of index for liver by cause from global burden of disease PubMed Scopus Google of by Chronic Disease B C liver cases, in increase and and North number of number of number of number of number of of number of number of number of number of of of of rates in high rates in high rates in high rates in rates in from Global Burden of Disease Burden of Disease J.M. et mortality, of life and life for from to a for the Global Burden of Disease PubMed Scopus Google Scholar et M. M. et in and burden and quality of index for liver by cause from global burden of disease PubMed Scopus Google Scholar et Y. J. J. et al.Global burden of liver by and global by based on global burden of disease 11: PubMed Scopus Google Scholar and et G. J. M. on hepatitis B by the global burden of liver disease to hepatitis B and PubMed Scopus Google Scholar in a from Global Burden of Disease Burden of Disease J.M. et mortality, of life and life for from to a for the Global Burden of Disease PubMed Scopus Google Scholar et M. M. et in and burden and quality of index for liver by cause from global burden of disease PubMed Scopus Google Scholar et Y. J. J. et al.Global burden of liver by and global by based on global burden of disease 11: PubMed Scopus Google Scholar and et G. J. M. on hepatitis B by the global burden of liver disease to hepatitis B and PubMed Scopus Google Scholar In other data the rates of liver for major and Y. J. J. et al.Global burden of liver by and global by based on global burden of disease 11: PubMed Scopus Google Scholar in that the for liver from alcohol owing to owing to owing to and owing to other also between the in liver to and in while and liver a in are by and alcohol have a and Although liver to in globally, high SDI countries an in liver countries the increase and North Eastern and and Central the and prevalence of liver in between and while for the the of on that the global rate of liver in owing to in to and from there is between to M. M. et in and burden and quality of index for liver by cause from global burden of disease PubMed Scopus Google Y. J. J. et al.Global burden of liver by and global by based on global burden of disease 11: PubMed Scopus Google Scholar In on the global liver the most cause of for for of global H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar in the rate between and the number of deaths rates of liver from causes the the most for In this context, and NAFLD deaths are increasing while deaths from to the shows a Burden of Disease J.M. et mortality, of life and life for from to a for the Global Burden of Disease PubMed Scopus Google Scholar is an that the of and quality accessed: 2022Google Scholar In other for CLD include and are and are and most to CLD are the and the the Chronic Disease its of and M. a PubMed Scopus Google Scholar, G. M. et of a disease to quality of life in chronic liver PubMed Google Scholar, M. and of Chronic Disease C in clinical of chronic hepatitis 2016; Full Text Full Text PDF PubMed Google Scholar, M. et quality of life for fatty liver disease and 2017; PubMed Scopus Google Scholar, M. Younossi I. A. of Chronic Disease for nonalcoholic in nonalcoholic Hepatol. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar, M. Younossi I. A. and of a hepatitis health-related PubMed Scopus Google Scholar, M. Younossi I. A. Younossi of in chronic hepatitis C the Chronic Disease C 2018; Full Text Full Text PDF PubMed Scopus Google Scholar is the and while is the of Chronic the and of a and impairment PubMed Google Scholar, A. et al.The of Chronic of 4 of the Scholar, J. et al.The to and

Tissue-resident immune cells are important for organ homeostasis and defense. The epithelium may contribute to these functions directly or by cross-talk with immune cells. We used single-cell RNA sequencing to resolve the spatiotemporal immune topology of the human kidney. We reveal anatomically defined expression patterns of immune genes within the epithelial compartment, with antimicrobial peptide transcripts evident in pelvic epithelium in the mature, but not fetal, kidney. A network of tissue-resident myeloid and lymphoid immune cells was evident in both fetal and mature kidney, with postnatal acquisition of transcriptional programs that promote infection-defense capabilities. Epithelial-immune cross-talk orchestrated localization of antibacterial macrophages and neutrophils to the regions of the kidney most susceptible to infection. Overall, our study provides a global overview of how the immune landscape of the human kidney is zonated to counter the dominant immunological challenge.

, whereas GDF15 supplementation tempered the inflammatory response in macrophages upon lipid loading and lipopolysaccharide stimulation. This study provides insights into the pathophysiology of progressive fibrosing steatohepatitis, and proof of principle that transcriptomic changes represent potentially tractable and clinically relevant markers of disease progression.

IMPORTANCE: Sarcopenia, the age-related loss of muscle mass and strength/function, is an important clinical condition. However, no international consensus on the definition exists. OBJECTIVE: The Global Leadership Initiative in Sarcopenia (GLIS) aimed to address this by establishing the global conceptual definition of sarcopenia. DESIGN: The GLIS steering committee was formed in 2019-21 with representatives from all relevant scientific societies worldwide. During this time, the steering committee developed a set of statements on the topic and invited members from these societies to participate in a two-phase International Delphi Study. Between 2022 and 2023, participants ranked their agreement with a set of statements using an online survey tool (SurveyMonkey). Statements were categorised based on predefined thresholds: strong agreement (>80%), moderate agreement (70-80%) and low agreement (<70%). Statements with strong agreement were accepted, statements with low agreement were rejected and those with moderate agreement were reintroduced until consensus was reached. RESULTS: 107 participants (mean age: 54 ± 12 years [1 missing age], 64% men) from 29 countries across 7 continents/regions completed the Delphi survey. Twenty statements were found to have a strong agreement. These included; 6 statements on 'general aspects of sarcopenia' (strongest agreement: the prevalence of sarcopenia increases with age (98.3%)), 3 statements on 'components of sarcopenia' (muscle mass (89.4%), muscle strength (93.1%) and muscle-specific strength (80.8%) should all be a part of the conceptual definition of sarcopenia)) and 11 statements on 'outcomes of sarcopenia' (strongest agreement: sarcopenia increases the risk of impaired physical performance (97.9%)). A key finding of the Delphi survey was that muscle mass, muscle strength and muscle-specific strength were all accepted as 'components of sarcopenia', whereas impaired physical performance was accepted as an 'outcome' rather than a 'component' of sarcopenia. CONCLUSION AND RELEVANCE: The GLIS has created the first global conceptual definition of sarcopenia, which will now serve to develop an operational definition for clinical and research settings.